Improved Survival in Vascular Pythiosis With Surgery and Azithromycin, Doxycycline, and Itraconazole Therapy: A Phase II Multicenter, Open-Label, Single-Arm Trial
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf062 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Pattama Torvorapanit und 28 weiteren Autor:innen. Beteiligte Einrichtung: Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Hauptthemen laut MEDLINE: Azithromycin, Doxycycline, Itraconazole, Pythiosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Health Systems Research Institute, Ratchadapiseksompotch Research Fund, Chulalongkorn University.
Abstract (Originalsprache)
Background
Vascular pythiosis, caused by Pythium insidiosum, is a life-threatening disease with high mortality rate in patients with residual disease post-surgery. This study evaluated the effectiveness of a combination therapy of surgery, azithromycin, doxycycline, and itraconazole.
Methods
In this open-label, Phase II multicenter trial, 51 patients were enrolled. Patients were categorized based on residual disease post-surgery (unresectable lesions, incomplete resection, or persistent symptoms). Patients with residual disease received azithromycin (500 mg daily), doxycycline (100 mg twice daily), and itraconazole (200 mg thrice daily) until beta-d-glucan (BDG) levels were negative (<80 pg/mL) for 3 months. Those without residual disease received the same regimen for 6 months. Outcomes included all-cause mortality at 6 months, adverse events, changes in BDG levels over time, and factors associated with residual disease and mortality.
Results
At 6 months, the all-cause mortality rate was 15.7%. Mortality in patients with residual disease was 31.5% compared to 6.25% for those without (P = .04). Lesions above the popliteal artery were a significant predictor of residual disease (incidence rate ratio [IRR] 3.20, 95% confidence interval [CI]: 1.08–11.70). BDG levels decreased over time (odds ratio [OR] 0.82, 95% CI: .77–.88 per week, P < .001) but remained higher in the residual disease group (OR 4.29, 95% CI: 1.55–11.92)
Conclusions
The combination therapy of surgery, azithromycin, doxycycline, and itraconazole improves survival in patients with vascular pythiosis, including those with residual disease. This regimen is well tolerated and should be considered a standard of care, with further research needed for long-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
- Department of Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
- Department of Transfusion Medicine and Clinical Microbiology, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.
- Research Unit of Medical Mycology Diagnosis, Chulalongkorn University, Bangkok, Thailand.
- Department of Medicine, Jackson Memorial Hospital/University of Miami, Miami, Florida, USA.
- Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Pattama Torvorapanit, Navaporn Worasilchai, Kasama Manothummetha, Karan Srisurapanont, Achitpol Thongkam, Nattapong Langsiri, Surachai Leksuwankun, Tanaporn Meejun, Jaedvara Thanakitcharu, Bhoowit Lerttiendamrong, Nuttapon Susaengrat, Nipat Chuleerarux, Sunee Chayangsu, Rattagan Kajeekul, Watchara Wattanasoontornsakul, Parichart Sakulkonkij, Jaruwan Diewsurin, Kanokwan Laohasakprasit, Ariya Chindamporn, Rongpong Plongla, Nitipong Permpalung
Förderung
- Health Systems Research Institute
- Ratchadapiseksompotch Research Fund
- Chulalongkorn University
Zitieren
APA
Torvorapanit, P., Worasilchai, N., Manothummetha, K., Srisurapanont, K., Thongkam, A., Langsiri, N., Leksuwankun, S., Meejun, T., Thanakitcharu, J., Lerttiendamrong, B., Susaengrat, N., Chuleerarux, N., Siriyakorn, N., Watcharasuwanseree, S., Suparatanachatpun, P., Chayangsu, S., Khemla, S., Kajeekul, R., Wattanasoontornsakul, W., …, & Permpalung, N. (2025). Improved Survival in Vascular Pythiosis With Surgery and Azithromycin, Doxycycline, and Itraconazole Therapy: A Phase II Multicenter, Open-Label, Single-Arm Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf062
Vancouver
Torvorapanit P, Worasilchai N, Manothummetha K, Srisurapanont K, Thongkam A, Langsiri N, et al. Improved Survival in Vascular Pythiosis With Surgery and Azithromycin, Doxycycline, and Itraconazole Therapy: A Phase II Multicenter, Open-Label, Single-Arm Trial. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf062
BibTeX
@article{Torvorapanit2025,
author = {Torvorapanit, Pattama and Worasilchai, Navaporn and Manothummetha, Kasama and Srisurapanont, Karan and Thongkam, Achitpol and Langsiri, Nattapong and Leksuwankun, Surachai and Meejun, Tanaporn and Thanakitcharu, Jaedvara and Lerttiendamrong, Bhoowit and Susaengrat, Nuttapon and Chuleerarux, Nipat and Siriyakorn, Nirada and Watcharasuwanseree, Sureerat and Suparatanachatpun, Pinyo and Chayangsu, Sunee and Khemla, Supphachoke and Kajeekul, Rattagan and Wattanasoontornsakul, Watchara and Bansong, Ratiporn and Sakulkonkij, Parichart and Wongkamhla, Thanyarak and Diewsurin, Jaruwan and Laohasakprasit, Kanokwan and Kongsakpaisal, Prasopchai and Chayapum, Poom and Chindamporn, Ariya and Plongla, Rongpong and Permpalung, Nitipong},
title = {Improved Survival in Vascular Pythiosis With Surgery and Azithromycin, Doxycycline, and Itraconazole Therapy: A Phase II Multicenter, Open-Label, Single-Arm Trial},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf062}
}
EUVIMED